Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

Progressive Familial Intrahepatic Cholestasis 1

Progressive Familial Intrahepatic Cholestasis in Indian Children – Establishing an Indian PFIC Registry A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Expanded Access Protocol for an Intermediate Size Population – RAVICTI for Byler Disease Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) Buphenyl Therapy for Byler’s Disease